• What Sets Neogenix Oncology Apart...
  • The Target
    The Target
    Our monoclonal antibodies are designed to target
    the tumor without harming healthy cells.
    >> Read More
  • The Technology
    The Technology
    We have the advantage of owning a library of cancer
    vaccines, several of which have demonstrated
    success in human trials.
    >> Read More
  • The Timing
    The Timing
    Our unique platform, combined with breakthroughs in
    biotechnology, enable us to produce targeted antibodies
    that weren’t possible just a few years ago.
    >> Read More
  • Neogenix Oncology:
    Real Hope for Cancer Patients
UPCOMING / RECENT EVENTS

June 1-5, 2012
Event: ASCO's 2012 Annual Meeting
Where: Chicago, IL
What: Neogenix Oncology will present "A phase 1 safety study of NPC-1C: A novel, therapeutic antibody to treat pancreas and colorectal cancers" at ASCO's annual meeting being held at McCormick Place in Chicago.
Click for event details       view poster      

January 19-21, 2012
Event: ASCO's 2012 Gastrointestinal Cancers Symposium
Where: San Francisco, CA
What: Dr. Michael Morse of Duke University Medical Center will present a poster pertaining to the Neogenix clinical trial at Duke, entitled: "A Phase I/IIA Safety Study of NPC-1C: A Novel Therapeutic Antibody to Treat Pancreas and Colorectal Cancers"
Click for event details      view poster      



> > Read More

CEO PHILIP M ARLEN, MD:
"What Sets Us Apart..."

THERAPEUTICS

Neogenix Oncology
has the advantage of proprietary antibodies
that are designed to target tumors with precision.
The company is among the leaders in biotherapeutics, which is opening the door to powerful new treatments. Currently, Neogenix Oncology is developing its first product candidate for pancreatic and colorectal cancer—Ensituximab (also known as NEO-101, and formerly NPC-1C). Other therapeutic candidates in development include NEO-201 (formerly h16C3) and NEO-301 (formerly 31.1C).

> Read More
DIAGNOSTICS

Neogenix Oncology is also developing a serum (blood) ELISA test for pancreatic and colorectal cancer, which holds promise both for detecting cancers in their early stages and predicting who will respond to our therapeutics. The goal is to produce reliable and simple tests in blood and tissue (IHC). These tests may also serve as companion diagnostics to our therapeutic program.



> Read More
Videotaped remarks by Ted Sorensen, former Vice Chairman of Neogenix Oncology, at the company’s Scientific Advisory Board meeting, October 2010.
Neogenix Oncology CEO Philip Arlen discusses advances in fighting pancreatic cancer with NBC’s Chuck Scarborough